GlobeImmune is engaged in the development of therapeutic Tarmogen vaccines for the treatment of cancer and infectious diseases.Read more
GlobeImmune's revenue is the ranked 23th among it's top 10 competitors. The top 10 competitors average 2.3B. Over the last four quarters, GlobeImmune's revenue has decreased by 26.2%. Specifically, in Q1 2016's revenue was $ < 1M; in Q4 2015, it was $1M; in Q3 2015, it was $2.9M; in Q2 2015, GlobeImmune's revenue was $1.3M.
No recent acquisitions found related to GlobeImmune
No recent investments found related to GlobeImmune